Navigation Links
Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Date:8/19/2007

kidney injury caused by ischemia-reperfusion. Our drug could potentially offer a lifesaving treatment for this severe disease, which exhibits high rates of morbidity and mortality and represents a very serious unmet medical need. We have an open IND for AKIi-5 and expect to initiate a Phase I trial for the prevention of ARF through the systemic delivery of AKIi- 5 in patients undergoing major cardiac surgery. Based on publicly available information, we believe that this will be the first human clinical trial involving the systemic delivery of siRNA."

About AKIi-5

AKIi-5 is a synthetic, chemically modified siRNA molecule designed to temporarily inhibit the expression of p53, a gene which plays a significant role in ARF by inducing tubular cell death (apoptosis) in response to injury. AKIi-5 is based on Quark's proprietary, patented concept of temporary and reversible inhibition, for therapeutic purposes, of the expression of the transcription factor human p53, which is associated with DNA repair and apoptosis. Using RNA interference technology to temporarily inhibit p53 in acute settings such as acute kidney injury, apoptosis is delayed thereby allowing natural repair mechanisms to restore normal DNA and cellular integrity. The AKIi-5 molecule was designed and patented by Quark. The Company has licenses for AtuRNAi(TM) technology from Silence Therapeutics and additional RNAi intellectual property from Alnylam.

About Acute Renal Failure (ARF)

ARF is a syndrome characterized by a rapid decline of kidney function leading to death in a high percentage of cases. Major cardiac surgery is one of the many causes of ARF. During cardiac bypass surgery, lack of oxygen caused by reduced local blood flow to the kidneys, followed by rapid reintroduction of oxygen, or reperfusion, to the kidneys upon removal of the patient from cardiopulmonary bypass, initiates a chain of events that can lead to ARF. Currently, there are no approved drug therapies that effec
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
3. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
4. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data at Society Of Nuclear Medicine 2007 Annual Meeting
5. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 China Biologic Products, Inc. (NASDAQ: ... integrated plasma-based biopharmaceutical company in China ... second quarter 2014 financial results on Tuesday, August 5, ... Company,s management will hold a conference call at 8:00 ... 8:00 p.m., Beijing Time on August 6, 2014, to ...
(Date:7/29/2014)... , July 29, 2014 , ... /Oxymorphone clinical development program has commenced , ... Australia during Q4 2014 , ... States in 1H 2015 Australian drug ... on its opioid transdermal patch programs after its recent announcement of ...
(Date:7/29/2014)... ROCKLAND, Massachusetts , July 29, 2014 ... an international Phase II study investigating the efficacy and safety ... mMCC is a rare and aggressive skin cancer ... explored in a seven cohort Phase I clinical trial for ... patients  , EMD Serono, Inc., a subsidiary of ...
Breaking Medicine Technology:China Biologic to Report Second Quarter 2014 Financial Results 2China Biologic to Report Second Quarter 2014 Financial Results 3Phosphagenics Provides Update on Opioid Patch Program 2Phosphagenics Provides Update on Opioid Patch Program 3Phosphagenics Provides Update on Opioid Patch Program 4Phosphagenics Provides Update on Opioid Patch Program 5Phosphagenics Provides Update on Opioid Patch Program 6EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 2EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 4EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 5
... First Extensive Report of Bile Acid Aberration in Type 2 Diabetes ... ... N.J., June 9 /PRNewswire-FirstCall/,-- KineMed, Inc., and Daiichi Sankyo, Inc., announced ... people with type 2,diabetes which may suggest a newly identified underlying ...
... 9 Pharmacyclics, Inc.,(Nasdaq: PCYC ) today ... orally available, selective inhibitor of Bruton,s tyrosine,kinase, or ... model,for rheumatoid arthritis (RA). The data were presented ... being held this,week in Boston, MA., Researchers ...
Cached Medicine Technology:New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 2New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 3New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 4New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 5New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 6New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 7Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 2Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 3Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 4
(Date:7/29/2014)... According to an article in the Daily ... a 52 year old woman in India. The surgery took ... had no idea that she had such a large tumor ... for years, but did not connect it to a possible ... the massive uterine fibroid after Latha was admitted for heavy ...
(Date:7/29/2014)... Little Rock, AR (PRWEB) July 29, 2014 ... S.Res.518 , a resolution declaring the week of October ... the value of case management in improving healthcare outcomes ... Pryor (D-AR) and Senator John Boozman (R-AR), with support ... American Case Management Association to honor case management professionals ...
(Date:7/29/2014)... Bethesda, Maryland (PRWEB) July 29, 2014 ... has been named a 2014 ASAE Power of ... Flu-Focused," a public awareness campaign to encourage everyone age ... annually. , ASAE recognized NFID for its power ... drive awareness and action among consumers and professionals about ...
(Date:7/29/2014)... Award-winning inventor Michael Croix has launched an Indiegogo campaign for ... embarrassing odors in the office. PoofPad is a discrete bag ... desk drawer. This compact packaging is designed for ease of ... the pad and poof away! , “We’ve all been there. ... appears out of nowhere. It’s embarrassing and unpleasant for everyone ...
(Date:7/29/2014)... Recognition, and Control (A.R.C.) Against Depression" was written by ... men to heed the call to self-help.. , Ray J. ... no job, leaving Raymond with a mortgage payment he could ... the emotional disturbance was so great that they put him ... to the root of his problems. , Raynond says, “Even ...
Breaking Medicine News(10 mins):Health News:World’s Largest Uterine Fibroid Removed from Patient 2Health News:World’s Largest Uterine Fibroid Removed from Patient 3Health News:CMSA Supports National Case Management Week Resolution Introduced in US Senate 2Health News:National Foundation for Infectious Diseases Receives Top ASAE Honors for Keeping the Nation Flu-Focused 2Health News:Award-Winning Inventor Michael Croix Launches an Indiegogo Campaign for PoofPad 2Health News:Award-Winning Inventor Michael Croix Launches an Indiegogo Campaign for PoofPad 3Health News:SBPRA Announces the Release of Its Newest Title, "Acceptance, Recognition, and Control (A.R.C.) Against Depression" 2
... HIV-positive head and neck cancer patients respond well to ... non-HIV-positive patients, despite prior reports to the contrary, according ... International Journal of Radiation OncologyBiologyPhysics , an official ... , Patients with HIV have a significantly higher risk ...
... A new program designed to create comprehensive, integrated, whole-person ... a $3.9 million grant from the Colorado Health Foundation. ... in the Department of Family Medicine at the University of ... and national leaders from the mental health, substance use, and ...
... , TUESDAY, Jan. 18 (HealthDay News) -- Seeing ... smokers, brains to plan the same motions, new research shows. ... brain activity in 17 smokers and 17 nonsmokers as they ... scenes, the smokers, brains showed increased activity in areas involved ...
... TORONTO, ON Adult children of divorce are more likely to ... suggests new research from the University of Toronto , In ... Psychiatry Research, investigators examined gender specific differences among a ... divorce before the age of 18. The study found that ...
... By Jenifer Goodwin HealthDay Reporter , ... reports from patients suggest that a controversial treatment for ... but many physicians remain highly skeptical of the ... Paolo Zamboni, a vascular surgeon from Italy, published an ...
... Rochester Institute of Technology indicates that the incidence of ... more than 25 percent higher among deaf and hard-of-hearing ... a direct correlation between childhood maltreatment and higher rates ... The study, which was presented at the 2010 ...
Cached Medicine News:Health News:HIV-positive head and neck cancer patients benefit from radiation therapy 2Health News:New program targeting whole-person health care gets major grant 2Health News:Smoking Scenes in Movies Light Up Smokers' Brains 2Health News:Parental divorce linked to suicidal thoughts 2Health News:Vein-Opening Treatment for MS Stirs Controversy 2Health News:Vein-Opening Treatment for MS Stirs Controversy 3Health News:Vein-Opening Treatment for MS Stirs Controversy 4Health News:Study: Abuse rates higher among deaf and hard-of-hearing children compared with hearing youths 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: